

Pavle Repovic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1129137/publications.pdf>

Version: 2024-02-01

26
papers

1,014
citations

516215

16
h-index

580395

25
g-index

27
all docs

27
docs citations

27
times ranked

1651
citing authors

#	ARTICLE	IF	CITATIONS
1	MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 561-572.	1.4	5
2	Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19. <i>Neurology and Therapy</i> , 2022, , 1.	1.4	0
3	The validity, responsiveness, and score interpretation of the PROMIS [®] Physical Function 15a short form in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 62, 103753.	0.9	2
4	The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset. <i>Journal of Neurology</i> , 2022, 269, 5319-5327.	1.8	4
5	Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND. <i>Neurology and Therapy</i> , 2021, 10, 169-182.	1.4	4
6	Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 96, e111-e120.	1.5	24
7	Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis?. <i>European Journal of Neurology</i> , 2021, 28, 2115-2120.	1.7	12
8	Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 711-715.	1.7	4
9	Standardizing fatigue measurement in multiple sclerosis: the validity, responsiveness and score interpretation of the PROMIS SF v1.0 8a " Fatigue (MS) 8a. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103117.	0.9	10
10	Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642199399.	1.5	12
11	Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS. <i>Multiple Sclerosis Journal</i> , 2021, , 135245852110636.	1.4	1
12	COVID-19 in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e783.	3.1	34
13	Management of Multiple Sclerosis Relapses. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 655-669.	0.4	22
14	Iron-Insensitive Quantitative Assessment of Subcortical Gray Matter Demyelination in Multiple Sclerosis Using the Macromolecular Proton Fraction. <i>American Journal of Neuroradiology</i> , 2018, 39, 618-625.	1.2	27
15	Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study. <i>Clinical Therapeutics</i> , 2018, 40, 2077-2087.	1.1	29
16	Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2018, 379, 846-855.	13.9	201
17	Fast Whole-Brain Three-dimensional Macromolecular Proton Fraction Mapping in Multiple Sclerosis. <i>Radiology</i> , 2015, 274, 210-220.	3.6	63
18	Treatment of Multiple Sclerosis Exacerbations. <i>Neurologic Clinics</i> , 2011, 29, 389-400.	0.8	28

#	ARTICLE	IF	CITATIONS
19	Anion and Solvent Effects upon the Structures of Platinum(II) Complexes with Thiocrown Ligands: The Crystal Structures of [Pt(9S3)2](PF6)2·2 CH3NO2, [Pt(9S3)2](BF4)2·2 CH3NO2, [Pt(9S3)2](OTf)2·2 CH3NO2 and [Pt(18S6)](BF4)2. European Journal of Inorganic Chemistry, 2005, 2005, 479-485.		20
20	Oncostatin M enhances the expression of prostaglandin E2 and cyclooxygenase-2 in astrocytes: Synergy with interleukin-1?, tumor necrosis factor-?, and bacterial lipopolysaccharide. Glia, 2003, 42, 433-446.	2.5	49
21	Oncostatin-M induction of vascular endothelial growth factor expression in astrogloma cells. Oncogene, 2003, 22, 8117-8124.	2.6	58
22	Prostaglandin E ₂ is a Novel Inducer of Oncostatin-M Expression in Macrophages and Microglia. Journal of Neuroscience, 2002, 22, 5334-5343.	1.7	66
23	Oncostatin M Regulation of Interleukin-6 Expression in Astrocytes. Journal of Neurochemistry, 2002, 75, 563-575.	2.1	68
24	Optimization of glycolysis: new discussions. Biochemical Education, 1999, 27, 12-13.	0.1	29
25	Interleukin-6 (IL-6) Production by Astrocytes: Autocrine Regulation by IL-6 and the Soluble IL-6 Receptor. Journal of Neuroscience, 1999, 19, 5236-5244.	1.7	208
26	Optimization of glycolysis: A new look at the efficiency of energy coupling. Biochemical Education, 1997, 25, 204-205.	0.1	34